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Abstract
Background: CpG island methylator phenotype (CIMP), in which multiple genes concordantly methylated, has
been demonstrated to be associated with progression, recurrence, as well as overall survival in some types of
cancer.
Methods: We examined the promoter methylation status of seven genes including P16, CDH1, GSTP1, DAPK, XAF1,
SOCS1 and SYK in 65 cases of HCC treated with LT by methylation-specific PCR. CIMP+ was defined as having three
or more genes that are concordantly methylated. The relationship between CIMP status and clinicopathological
parameters, as well as tumor recurrence was further analyzed.
Results: CIMP+ was more frequent in HCC with AFP > 400 ng/ml than those with AFP ≤ 400 ng/ml (P = 0.017).
In addition, patients with CIMP+ were prone to have multiple tumor numbers than those with CIMP- (P = 0.007).
Patients with CIMP+ tumors had significantly worse recurrence-free survival (RFS) than patients with CIMP-tumors
by Kaplan-Meier estimates (P = 0.004). Multivariate analysis also revealed that CIMP status might be a novel
independent prognostic factor of RFS for HCC patients treated with LT (HR: 3.581; 95% CI: 1.473-8.710, P = 0.005).
Conclusion: Our results suggested that CIMP could serve as a new prognostic biomarker to predict the risk of
tumor recurrence in HCC after transplantation.
Background
Primary liver cancer is one of the most common solid
tumors, rated fifth in incidence and the third in mortal-
ity worldwide [1]. Hepatocellular carcinoma (HCC)
accounts for between 85% and 90% of primary liver can-
cers [2]. China is one of the highest prevalent areas of
HCC, mainly because of chronic hepatitis B carriers
accounting for more than 10% of its population [3]. The
prognosis of patients with HCC remains generally poor,
even after surgical resection or chemotherapy. Liver
transplantation (LT) offers a potential curative option
for patients with small HCC, but post-operative tumor
recurrence remains one of the most prevalent causes of
unsatisfactory long-term survival [4]. Therefore, identifi-
cation of reliable prognostic factors for tumor recur-
rence and death could have significant clinical
importance. Patients in a low-risk group, for example,
would be more appropriated candidates for LT, which is
benefit for establishing a new set of election and prog-
nostic criteria.
Over the past few years, both our group and others
have focused on searching for reliable molecular bio-
markers to better distinguish subtypes of patients who
have different risk of tumor recurrence in HCC patients
treated with LT [5-7]. Investigators in our group have
established a retrospective cohort of HCC patients who
underwent LT at our institution, and analyzed some
potential tumor biomarkers within this valuable clinical
research database. Yet little is known about the
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diction after LT.
Recently, as an important mechanism of inactivation
of tumor suppressor genes (TSGs), DNA methylation
has shown promise as a potential biomarker for early
detection, therapy monitoring, assessment of prognosis
or prediction of therapy response in a variety of malig-
nancies [8-11], including HCC [12,13]. However, in
recent years, a methylator phenotype based on concur-
rently methylated of multiple TSGs, also called the CpG
island methylator phenotype (CIMP), is being consid-
ered to have more clinical value than a single gene
methylation. [14]. Numerous studies have suggested that
CIMP status might be associated with progression,
recurrence, as well as long-term survival in different
types of cancer, such as non-small cell lung cancer
(NSCLC) [15], acute lymphoblastic leukemia [16], neu-
roblastoma [17], esophageal adenocarcinoma [18]and
colon cancer [19]. In HCC, Zhang et al. [20] detected a
panel of CIMP including nine TSGs in 50 HCC patients
with surgical resection, and found that CIMP status was
correlated with elevated preoperative serum AFP level.
More recently, Cheng et al. [21] examined the promoter
methylation status of 10 genes in 60 cases of HCC with
surgical resection, and the results suggested that CIMP
could serve as a molecular marker of late stage and
poorly prognostic HCC development. However, the pre-
dictive value of CIMP for tumor recurrence in HCC
patients, especially in HCC treated with LT, remains
unclear. Therefore, it is worthy of developing a panel
consist of representative genes from key molecular path-
ways or a selection reflecting the CIMP status of HCC
patients treated with LT.
In this study, in order to investigate the predictive
value of the methylation status of a panel of TSGs on
tumor recurrence in HCC, the promoter methylation of
twelve TSGs that belonging to the molecular pathways
involved in cell immortalization and transformation
included P 1 6 ,C D H 1 ,G S T P 1 ,D A P K ,M G M T ,X A F 1 ,
TIMP3, SOCS1, SFRP1, TMS1, SYK and DKK1 were
initially examined in a small cohort of 20 cases of HCC
treated with LT [12,22-31] (Table 1). These genes were
selected because they have been demonstrated to be
methylated frequently in HCC and other malignancies.
Resultantly, seven target genes with methylation fre-
quency more than 40% were brought to the panel of
CIMP (including P16, CDH1, GSTP1, DAPK, XAF1,
SOCS1 and SYK). Then the examination of methylation
status of these seven individual genes was expanded to
total 65 cases of hepatitis B virus (HBV)-associated
HCC treated with LT. The relationship between aber-
rant methylation pattern of multiple genes and clinico-
pathological parameters, as well as tumor recurrence
was further analyzed in this study. The aim of the
present study was to determine whether CIMP is a
potentially predictive biomarker of tumor recurrence in
HCC patients following LT.
Methods
Patients and specimens
A total of sixty-five patients (59 men, 6 women; mean
age 48.8 years; range, 29-67 years) who underwent LT
in our institution between 2003 and 2005 were enrolled
in this retrospective study according to the same eligibil-
ity criteria as our recent study [5]: (a) The diagnosis of
HCC were confirmed by histopathologic examination
either before or after transplantation (as an incidental
finding); (b) all patients included in this retrospective
study were HBV-positive; (c) The clinical and laboratory
data was obtained for all 65 patients, including portal
vein tumor thrombi (PVTT), preoperative alpha-fetopro-
tein (AFP) level, histopathologic grading, tumor size,
and tumor number; (d) all these patients were Han Chi-
nese; (e) none of these patients received preoperative
adjuvant antineoplastic therapy. The follow-up course
and diagnosis criteria of recurrence have been shown in
the previous study [7]. This study was approved by local
ethic committee, and informed consent was obtained
according to the Declaration of Helsinki. All the tissue
samples from primary tumors were stored at -80°C
tissue banks.
Methylation-specific polymerase chain reaction (MSP)
Aberrant promoter methylation of these genes was
determined by method of methylation-specific polymer-
ase chain reaction (MSP) as reported by Herman et al
[32]. Genomic DNA was isolated from frozen liver tissue
using DNeasy Tissue Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions. DNA samples
were modified using EZ DNA Methylation Golden Kit
(Zymo Research, Orange, CA). MSP distinguishes
unmethylated alleles of a given gene based on DNA
sequence alterations after bisulfite treatment of DNA,
which converts unmethylated but not methylated cyto-
sines to uracils. Subsequent polymerase chain reaction
using primers specific to sequences corresponding to
either methylated or unmethylated DNA sequences was
then performed. DNA methylation of CpG islands was
then determined by PCR using specific primers for
either methylated or unmethylated DNA. Two sets of
primers were used to amplify each region of interest:
one pair recognized a sequence in which CpG sites were
unmethylated (bisulfite-modified to UpG), and the other
recognized a sequence in which CpG sites were methy-
lated (unmodified by bisulfite treatment). The MSP pri-
mer sequences of each gene for the unmethylated and
methylated reactions were determined as described pre-
viously [12,22-31]. The PCR amplifications were carried
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25 μl containing 25 pM of each primers, 25 μMd e o x y -
nucleoside triphosphates, 30 ng of bisulfate-treated
DNA, 1 U of hot-start Taq polymerase (Takara, Shiga,
Japan) and the respective buffers. Hot start polymerase
chain reaction was performed at 95°C hot start for 10
minutes followed by 30 repetitive cycles consisting of
denaturation at 95°C for 30 seconds, annealing at speci-
fic temperature for 30 seconds, and extension at 72°C
for 30 seconds, then finished with a final 10-minute
extension. To prepare the positive methylation control,
1 μg of genomic DNA from normal human liver was
treated in vitro with SssI methyltransferase (NEB, Bev-
erly, MA), yielding completely methylated DNA at all
CpG rich regions. Bisulfite-modified DNA from normal
human liver served as a positive control for the
unmethylated alleles. Water blanks were also included
with each assay. The PCR products were analyzed on
ethidium bromide-stained 2% agarose gel. No clinico-
pathological or follow-up data were revealed to the
bench researchers until the MSP results were finalized.
Statistical analysis
Statistical comparisons were performed using either the
Pearson’s chi-square test or two sided Fisher’s exact test,
as appropriate. Recurrence-free survival (RFS) was
defined as the interval from the operation day to date of
documented tumor recurrence or date of the most
recent follow-up visit if recurrence did not occur. Log-
rank tests were used to identify the number of methy-
lated genes that was most predictive of RFS. Survival
curves of the patients were compared using the Kaplan-
Meier method and analyzed using the Log-rank test. For
a given gene, a univariate Cox proportional hazard
regression model was used to estimate the effect of
methylation status (partially or completely methylated
versus unmethylated) on the relative hazard of risk for
tumor recurrence. The same method was also used to
evaluate the univariate correlations between CIMP sta-
tus or clinicalpathological variables, and tumor recur-
rence. Only variables with significance in univariate
analysis were performed in the multivariate analysis
using Cox proportional hazard model.
Data analysis was performed using Statistical Package
for Social Sciences (SPSS) version 16.0 for Windows
(SPSS Inc, Chicago, IL). All tests were two tailed and
P < 0.05 was considered statistically significant.
Results
Frequency of CpG island hypermethylation in HCC
The frequency of promoter methylated of the gene
included in the panel was 51% (33 of 65) for P16,4 3 %
(28 of 65) for CDH1, 55% (36 of 65) for SOCS1, 60% (39
of 65) for GSTP1, 52% (34 of 65) for SYK, 66% (43 of
65) for XAF1, 52% (34 of 65) for DAPK1. The other five
genes with the methylation frequency less than 40%
were not analyzed in the CIMP panel (5% for MGMT,
15% for TMS1, 20% for SFRP1, 25% for TIMP3, 15% for
DKK1). Representative examples of MSP assay results
are presented in Fig. 1. Overall, only two cases showed
no methylation of any of these genes.
Study of correlations between promoter methylation
status of each gene and clinicopathological characteris-
tics are summarized in Additional file 1. Overall, the
hypermethylation of GSTP1 was present more frequently
in patients with poor histopathologic grading (P = 0.003)
and multiple tumor numbers (P = 0.011). The hyper-
methylaton of XAF1 was present more frequently in
HCC, with AFP > 400 ng/ml than those with AFP ≤ 400
ng/ml (P = 0.007). Likewise, patients with methylated
DAPK were suffered from larger tumor size than those
with unmethylated DAPK promoter (P = 0.016). How-
ever, we found no significant associations between the
methylation status of P16, CDH1, SOCS1, SYK and the
Table 1 Genes investigated for methylation in HCC after LT
Gene Chromosomal Locations Function References
SFRP1 8p12-11.1 Wnt signaling pathway antagonist [30]
P16 9q21 Cell cycle regulation [22]
SYK 9q22 Signal transduction [12]
DAPK 9q34 Interferon-g, TNF-a, and FAS-induced apoptosis [25]
DKK1 10q11.1 Wnt signaling pathway antagonist [31]
MGMT 10q26 DNA repair [26]
GSTP1 11q13 Carcinogens and cytotoxic drug detoxification [24]
TMS1 16p11-12 Apoptosis regulation [25]
SOCS1 16p13.13 Regulator of cytokine signaling [29]
CDH1 16q22 Cell adhesion [23]
XAF1 17p13.2 Cell apoptosis [27]
TIMP3 22q13.1 Tissue invasion and metastasis [21]
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gender, PVTT, AFP level, histopathologic grading,
tumor size and tumor numbers.
The relative risk for tumor recurrence of methylation
status of an individual gene was shown in Additional file
2. Only methylaton of SYK was found to be prone to
recurrence (P = 0.046), which was similar to the pre-
vious study in HCC [12]. No significant correlation was
observed between tumor recurrence and methylation
status of any other individual gene.
Frequency of CIMP in HCC patients
Originally, CIMP-positive gastric cancer was defined as
a tumor with methylation at more than three genes [33].
CIMP was also defined by the average number of
methylated genes per tumor in several recent studies
[34,35]. However, a recent new study offered potential
markers to define a CIMP concept, in which the threds-
hold distinguishing CIMP+ from CIMP-samples was
chosen by minimizing the within-group sum of squared
errors [36]. In the present study, a methylation pheno-
type was defined on the basis of results of log-rank tests
of the effect of number of methylated genes on RFS as
reported by Yang [37]. The lowest P value in Table 2
was used to identify an optimal cutoff of the number of
methylated genes. Accordingly, CIMP status was classi-
fied as CIMP+ samples (with three or more methylated
genes) and CIMP-samples (with two or fewer methy-
lated genes). Of the HCCs, 72% (47 of 65) were CIMP+.
Correlation of CIMP with clinicopathological parameters
Using statistical analysis, we examined CIMP with
regard to HCC patient clinicopathologic parameters
(Table 3). A significant difference between CIMP status
and preoperative AFP level was being found in HCC
with LT (P = 0.017). Meanwhile, we found that CIMP+
was more frequent in HCC, with AFP > 400 ng/ml
(87%, 26/30) than those with AFP ≤ 400 ng/ml (60%,
21/35; P = 0.017). Likewise, patients with CIMP+ were
prone to have multiple tumor numbers than those with
CIMP- (P = 0.007). However, we found no significant
associations between the CIMP status with other clini-
copathological features like patient’s age and gender,
PVTT, histopathologic grading and tumor size. In addi-
tion, the results showed a correlation between CIMP
and Hangzhou criteria, which consider tumor size, his-
tological grading, and serum AFP level [38]. Patients
that exceeded the Hangzhou criteria had a higher CIMP+
Figure 1 Representative results of MSP for seven tumor suppressor genes.
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(84% vs. 57%, P = 0.017) (Table 3).
CIMP correlates with the risk of tumor recurrence
Recently, we used the Hangzhou criteria as a new cri-
teria for prognosis prediction of HCC patients post-LT,
and found those matched Hangzhou criteria had better
RFS than the others. In this study, when the 65 patients
were grouped according to the Hangzhou criteria, simi-
lar results were observed (P <0 . 0 0 1 ,d a t an o ts h o w n ) .
Consistently, the cumulative 3-year RFS rate in patients
with CIMP- is 64%, compared to that of 25% in patients
with CIMP+. The mean RFS for CIMP- patients was
significantly longer than that for CIMP+ patients by
Kaplan-Meier estimates (30.3 vs. 15.3 months, P =
0.004) (Fig. 2). Considering the association of CIMP and
Hangzhou criteria, the prognostic value of CIMP might
overlap with that of Hangzhou criteria. Therefore,
further segregation based on CIMP was applied to ana-
lyze the RFS in those who matched the Hangzhou cri-
teria or not, respectively. Resultantly, a trend toward
shorter RFS in CIMP+ than CIMP- was seen in both
patients who matched the Hangzhou criteria and those
exceeded the criteria, although there was no significant
difference(P = 0.101,0.113, respectively, data not shown).
Furthermore, Cox univariate analysis also revealed that
the clinicopathological variables could provide signifi-
cant predictive values for recurrence including preopera-
tive AFP level, tumor size and CIMP status (data not
shown). Multivariate analysis revealed that a larger
tumor size and CIMP+ could be independent prognostic
factors for RFS (Table 4).
Table 2 Results of Log-rank tests for effect of number of methylated genes on recurrence-free survival in 65 HCC
patients after LT
No. methylated
genes
No. patients with profile in total 27 recurrence-free
patients
No. patients with profile in total 38 recurrence
patients
P*
≥1 25 38 0.152
≥2 22 36 0.107
≥3 15 32 0.004
≥4 14 29 0.015
≥5 8 16 0.478
≥6 2 6 0.280
≥7 0 2 0.236
HCC, hepatocellular carcinoma; LT, liver transplantation.
*Log-rank test
Table 3 Association of CIMP with clinicopathological parameters
Variables Grading CIMP P*
negative n (%) positive n (%)
Age(Years) ≤50 8(22) 28(78)
> 50 10(34) 19(66) 0.272
Gender Female 2(33) 4(67)
Male 16(27) 43(73) 0.666
PVTT Negative 13(30) 31(70)
Positive 5(24) 16(76) 0.629
Preoperative AFP level(ng/ml) ≤400 14(40) 21(60)
> 400 4(13) 26(87) 0.017
Histopathologic grading Well+moderate 14(30) 33(70)
Poor 4(22) 14(78) 0.758
Tumor size(cm) ≤5 8(28) 21(72)
> 5 10(28) 26(72) 0.986
Tumor number Single 11(48) 12(52)
Multiple 7(17) 35(83) 0.007
Hangzhou criteria** Yes 12(43) 16(57)
No 6(16) 31(84) 0.017
PVTT, portal vein tumor thrombi; AFP, alpha-fetoprotein
** Apart from the presence of macrovascular invasion, Hangzhou criteria are matched if total tumor diameter ≤ 8 cm, or if, total tumor diameter > 8 cm, with
histopathologic grade I/II and AFP ≤ 400 ng/mL [38].
*Pearson’s Chi-square test or Fisher’s exact test.
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Recently, limited studies have confirmed the relationship
between CIMP status and the progression, as well as
prognosis of HCC with resection [20]. In this study, we
also found that the CIMP status of patients with HCC
after LT was closely associated with clinicopathological
parameters, such as preoperative AFP level and tumor
number. Furthermore, patients with CIMP+ tumors had
significantly shorter RFS than patients with CIMP-
tumors. To our best knowledge, this is the first investi-
gation to develop a marker panel for improved recur-
rence prediction in HCC patients treated with LT.
The significance of CIMP-positive phenotype that is
associated with distinct clinicopathologic features, such
as advanced tumor stage and poor differentiation, have
been best characterized in several types of malignancies
[10,11]. In HCC, Zhang et al detected the promoter
methylation status of nine genes in 50 pairs of HCC
cases, and reported that patients with CIMP + had
an elevated serum AFP level compare to that of CIMP-
[20]. In line with this finding, we found that CIMP+ was
more frequent in HCC with AFP > 400 ng/ml than
those with AFP ≤ 400 ng/ml (P = 0.017). Further studies
to clarify the relationship between AFP expression and
methylator phenotype in HCC progress are recom-
mended. Meanwhile, our results revealed that patients
with CIMP + displayed a higher frequency of tumor
multifocality than those with CIMP- (P = 0.007)
(Table 3), suggesting a strong association between CIMP
status and tumor numbers of HCC. Taken together,
these findings further support that CIMP is a marker
reflecting clinicopathologic features of human solid
tumors involving HCC, suggesting the potential impor-
tance of CIMP in cancer development and prognosis.
Based on the association between CIMP status and clini-
copathological parameters such as AFP level and tumor
numbers, we speculated that the CIMP might be corre-
lated to Hangzhou criteria, which is a new criteria for
patient selection and prognosis prediction of LT in
HCC patients [38]. Obviously, the present data demon-
strated this possibility. These results suggest that both
CIMP and Hangzhou criteria have the power to
reflecting the clinical and pathological factors of HCC.
Possible, CIMP status might be an epigenetic molecular
model of Hangzhou Criteria and have the similar poten-
tial ability to predict tumor recurrence after LT.
The prognostic role of CIMP status in HCC is unclear
and there is only limited information about the prognos-
tic significance of concordant gene methylation. A
recent report in 60 HCCs with surgical resection found
that metastasis was significantly different among patients
with different CIMP status [21]. Furthermore, patients
with high frequency CIMP tumors had significantly
worse survival than patients with intermediate frequency
or no CIMP tumors. These findings led us to investigate
the potential correlation of CIMP status and the risk of
tumor recurrence after LT. Similar to above finding, we
found that patients with CIMP- showed favorable RFS
than those with CIMP + (P = 0.004, Fig. 2). In order to
further assess the independent impact of the different
parameters on tumor recurrence, CIMP status as well as
other parameters with significant association in the uni-
variate analysis were included in the multivariate model.
Analysis of data showed patients with CIMP + conferred
a3 . 6 - f o l di n c r e a s ei nr e c u r r e n c er i s k ,w h i c hs u g g e s t e d
that CIMP status might be a novel independent factor
affecting tumor recurrence after LT (Table 4). Here, it
should be mentioned that there was one minor limita-
tion in this study. Although macrovascular invasion,
tumor size, preoperative AFP level, and histopathologic
grading have been proved to be independent prognostic
factors for HCC patients following LT in most previous
studies [6,7], Cox univariate analysis revealed that the
clinicopathological variables that could provide
Figure 2 Kaplan-Meier estimates of cumulative RFS in the 65
hepatocellular carcinoma patients treated with liver
transplantation according to the CIMP status. CIMP status was
classified as CIMP+ samples (with three or more methylated genes)
and CIMP- samples (with two or fewer methylated genes).
Table 4 Multivariate Cox regression analysis of variables
related to tumor recurrence at univariate analysis
Variable Relative risk of recurrence
(95% CI)
P*
Tumor size
> 5 cm vs. ≤5 cm 2.366 (1.186-4.720) 0.015
CIMP
positive vs. negative 3.581 (1.473-8.710) 0.005
*95% CIs and P values were calculated by the Cox proportional hazards
regression analysis.
Wu et al. BMC Cancer 2010, 10:399
http://www.biomedcentral.com/1471-2407/10/399
Page 6 of 8significant predictive value for tumor recurrence only
included preoperative AFP level, tumor size and CIMP
status in the present study. We do not yet have a clear
explanation for this result, but this is thought to at least
in part due to the small sample size. Despite this limita-
tion, these above findings suggested a major ability for
CIMP in tumor invasiveness of HCC. In CIMP+ tumors,
hypermethylated tumor suppressor-metastasis genes
become simultaneously silenced. Consequently, it contri-
butes to promoting proliferation and metastasis of
tumor cells, which may subsequently result in increased
risk of recurrence in patients with CIMP +. Given the
prognostic power of CIMP status, further investigations
are clearly warranted for a comparison of predictive
value between Hangzhou criteria or Milan criteria and
the CIMP marker in additional retrospective and pro-
spective cohorts.
The term CIMP has been used for a subset of tumors
with promoter methylation in multiple genes in many
tumors. However, it should be concerned that there is no
uniform selection pattern of CIMP in HCC up to now.
The main reasons include three points: First, as known to
all, methylation frequency of a certain gene varies among
HCC patients due to the difference of ethnic origin, etiol-
ogy background, and disease stages. In China, nearly 40%
donor livers are offered to HCC patients, who have more
hepatitis B related backgrounds and more advanced or
aggressive tumor characteristics than those in Western
countries [39]. Thus, it is almost impossible to establish a
same CIMP panel as Western countries. Secondly, unlike
in colon cancer, no systemic evaluation of a large, popula-
tion-based sample strongly supports the biologic role of
CIMP in HCC so far. Recently, Weisenberger et al. [36]
conducted a systematic, stepwise screen of large-scale CpG
island methylation markers using MethyLight technology
in colon cancer and determined relatively uniform CIMP
pattern. It would be worthwhile to develop a panel of
representative genes involved key molecular pathways in
HCC patients treated with LT using large-scale screen
technology. In the present study, CIMP status was classi-
fied as CIMP+ samples (with three or more methylated
genes) and CIMP- samples (with two or fewer methylated
genes). And the mean RFS for CIMP- patients was signifi-
cantly longer than that for CIMP+ patients (Fig. 2). These
findings provided a valuable exploration for the predictive
value of CIMP panel on tumor recurrence in HCC patients
following LT. The study should therefore be viewed as
hypothesis generating, to be followed by larger prospective
and multiethnic studies to confirm our findings.
Conclusion
In conclusion, Patients with CIMP+ had higher AFP
level, multiple tumor numbers and unfavourable out-
come. Furthermore, our study was the first one to
establish the CIMP model as an independent marker to
predict the risk of tumor recurrence in HCC after trans-
plantation. Future studies will be focused on combining
the CIMP pattern with Hangzhou criteria, and propos-
ing a more reasonable and optimized model for patient
selection and prognosis prediction, which will benefit
more HCC patients for LT.
Additional material
Additional file 1: Supplementary Table 1. Correlation between
methylation status of each of the seven genes investigated and
clinicopathological characteristics in HCC.
Additional file 2: Supplementary Table 2. Results of Cox regression
model for methylation status (partially or completely methylated versus
unmethylated) of each separate gene on the relative risk for tumor
recurrence.
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